Cytotron Therapy :: Treating Cancer Differently

CYTOTRON® has evolved using Magnetic Resonance Imaging (MRI) based on intrinsic proton density (PD) measurements of target tissue to manipulate biophysical cellular signalling. Highly complex Fast Radio Busts (FRB) in the safe radio frequency, in the presence of controlled, high, instantaneous Magnetic Resonance, is precisely focused on target tissues to alter the Transmembrane potential (TMP) of cells which triggers apoptosis (programmed cell death) and stops growth of solid tumours.

Cells in our body can multiply up to approx 50 times before becoming senescent, which means it can no longer further that process. After the 50th division, there is a flag planted down, where a protein called p53, a programmed cell death protein, is expressed. This ensures the cell doesn’t divide any further. This process is driven by the pro-apoptotic protein p53, which regulates apoptosis. Unfortunately, in cancer cells, this process doesn’t happen because the protein is mutated or is not expressed, as they do not receive the signal to do so. Naturally, these cells don’t know when to stop multiplying and eventually progress to grow as an organ in the body or a life form. As they grow, they land up with a resource crunch. Then, these cells look at forming new colonies and start spreading with their “survival instincts” taking over. Cancer produces a very special kind of cell, called EMT cells or cancer stem cells (CSCs), that spread to another location and then it builds up new colonies.

As long as the cancer is growing, the body’s immune system does not attack it. On the contrary, it protects the cancer tissue. Cancer cells take advantage of this situation, and conquer different organs of the body, until the body cannot function normally.

CYTOTRON® is used to non-invasively re-activate the body’s tumor suppression mechanism by targeting high precision, calibrated doses of fast radio bursts (FRB) - non-ionising, non-thermal electromagnetic waves at the tumor site.  This triggers the production of new tumor suppressing nucleoproteins which determines and flags that the cell is old enough to die. The moment this happens, the cell stops growing and the immune system flushes the cell out over a period of time. The cancer tissue may be recycled, and this therapy process also works to convert or transform the cancer stem cells into cells that don’t multiply. Depending on which stage of cancer you’re being treated at, it stops the cancer cells from spreading. The earlier you get the Cytotron therapy, the cancer gets arrested at that point. Once we stop the tumor from growing and spreading, there are other ways we can manage the disease.

CYTOTRON® acts on the mitochondrial membrane and interfere with communication between the gene transcription machinery and the protoplasmic glycoproteinic complexes involved in the promotion of cellular mitosis. Based on the outcomes reported in treating malignant lesions, the CYTOTRON®  induces such alterations of the TMP in a controlled manner, to modify cellular command and control and alter cellular activity to stabilize and arrest tumor progression.

No, Non-solid tumour like Leukemia and Multiple Myeloma is not possible to be treated with CYTOTRON®.

• The patient history and reports are scrutinized by the Medical Director /team of Doctors at the center. The reports that are required are latest PET-CT, Blood reports; CBC, LFT, RFT, Electrolytes, Serum Zinc, Copper, Magnesium, Iron, Vitamin D, Vitamin B12, HIV 1 & 2 Elisa, HCV Elisa, HBsAG Elisa, Anti Varicella, etc as required.
• Patient presence is a must during evaluation.
• A whole body MRI for tissue proton density determination is done to compute individualized dosimetry to target solitary (Single lesion /Brain) or multiple regions of interest (multiple lesion / widespread metastasis) in the whole body simultaneously.
• A 2D Proton Density (PD) sequence of the tumor is obtained on film and copied by the radiologist for use at the treatment center for dose planning
• A very low intensity Computerized Tomography (CT) guided surface marking of the Region of Interest (target tissue) is made by the radiologist.
• The CD containing PD images is loaded into the Cytotron Central Control Unit (CCU) and the region(s) of interest is/are identified. The largest and smallest diameter of each lesion is marked. A margin of 1-2 mm beyond the target area is marked to include any infiltrating, rapidly growing tumor cells around the lesion and included in the region of interest.
• The sequence of dose planning is set in motion automatically by the Central Control Unit, applying pre-planned proprietary algorithms
• The patient is dosed for one hour every day for a period of 28 consecutive days without a break. If there is break for more than 24 – 48 hours before the completion of the treatment period, the treatment has to start all over again.
• Cytotron device is operated ONLY by fully trained and Certified Cytotron technologist (Nursing & Para Nursing staff) and specialist (Medical doctors)

The therapy is for 28 hours spread over 28 days (One Hour/day). So far, over 800 patients have been treated with Cytotron, most of them in terminal stages.

One of the most striking differences that patients notice within 10-12 days of therapy is pain relief, without the need for medication. They are able to sleep better. They will also notice a marked sense of wellbeing and improved appetite. Overall survival and tumor stability and tumor progression is measured and followed up for 12 months. Over 71% terminally ill patients had stable disease one month after completion of Cytotron therapy. We maintain meticulous records of our patient’s progress and follow up, by way of both quality and quantity of life.

Patient will be reviewed periodically based on the blood reports, PET CT / MRI to compare and study the efficacy of the treatment in terms of measureable changes in dimensions, tumour volume and signal intensity differences between pre and post-treatment of targeted lesions. Regular review is a critical requirement of the treatment protocol as advised by the Medical Director of the center.

The Stay and food for the patient and one attendant is organised for the selected patients who will undergo the Dheergayu program along with Cytotron.